Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A pharmaceutical preparation for the treatment of tumor diseases, autoimmune diseases, cardiovascular diseases, infections, or viral diseases, comprising one or more salts ~~Salts~~ of guanidine derivatives corresponding to the formula



wherein

X represents ~~a valence bond, $-CH_2-NH-$,~~ $-CH_2-NH-NH-$ or $-CH=N-NH-$,

R represents a linear or branched C_1-C_{30} alkyl, C_3-C_{20} cycloalkyl, ~~adamantyl, norbornyl,~~ or tricyclodecyl~~, benzyl, furyl, pyridyl, anthracyl, naphthyl, phenanthryl, perinaphthyl or quinuclidinyl~~ residue, which can be substituted by one or more hydroxyl groups, C_1-C_4 alkoxy groups, C_1-C_4 alkyl groups and/or one or more halogen atoms or one or more amino groups, and

Z represents O-CO-Y, $O\text{-}S(O)_2\text{-}Y$, or $O\text{-}P(O)(OH)\text{-}Y$, wherein Y represents a linear or branched C_1-C_{12} alkyl, C_3-C_8 cycloalkyl, benzyl, furyl or pyridyl residue, which can be substituted by one or more hydroxyl groups, carboxylic acid groups, C_1-C_4 alkoxy groups, C_1-C_4 alkyl groups and/or one or more halogen atoms or one or more amino groups.

2. (Currently Amended) The preparation ~~Salt~~ according to Claim 1, wherein Z represents O-CO-Y.

3. (Currently Amended) The preparation ~~Salt~~ according to Claim 1 ~~2~~, wherein R represents a pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, cyclododecyl, tricyclo[~~5,2,1~~,5.2.1.$0^{2,6}$]-decyl, or bicyclo[~~2,2,1~~2.2.1]-~~cyclo~~hexyl ~~or toluyl~~ residue.

4. (Currently Amended) The preparation ~~Salt~~ according to Claim 1 ~~2~~, wherein R represents a decyl residue.

5. (Currently Amended) The preparation ~~Salt~~ according to Claim 1 ~~2~~, wherein Y is methyl, ethyl, propyl, isopropyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, hydroxyethyl or 2-hydroxy-2,3-dicarboxylic acid propyl.

6. (Cancelled)

7. (Currently Amended) The preparation ~~Salt~~ according to Claim 5 ~~2~~, wherein R represents a decyl residue~~; X represents $-CH_2-NH-NH-$ or $-CH=N-NH-$; and Y is methyl, ethyl, propyl, isopropyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, hydroxyethyl, or 2-hydroxy-2,3-dicarboxylic acid propyl~~.

8. (Currently Amended) The preparation ~~Salt~~ according to Claim 1 ~~2~~, said salt being undecylideneaminoguanidine acetate or undecylideneaminoguanidine lactate.

9. (Currently Amended) The preparation ~~Salt~~ according to Claim 1 ~~2~~, said salt being undecylideneaminoguanidine oenanthate or undecylideneaminoguanidine pelargonate.

10. (Currently Amended) The preparation ~~Salt~~ according to Claim 1 ~~2~~, said salt being undecylideneaminoguanidine decanoate.

11. (Currently Amended) The preparation ~~Salt~~ according to Claim 1 ~~2~~, said salt being undecylideneaminoguanidine hexanoate.

12. (Currently Amended) The preparation ~~Salt~~ according to Claim 1, wherein Z is O-$S(O)_2$-Y (sulfonic acid group), or O-P(O)(OH)-Y (~~phosphoric~~phosphonic acid group).

13. (Cancelled)

14. (Currently Amended) The preparation ~~Pharmaceutical preparation~~ according to Claim 1 ~~-13~~, further comprising a ~~common~~ pharmaceutically acceptable additives and/or excipients.

15. (Currently Amended) Method for the preparation of a pharmaceutical preparation for the treatment of tumor diseases, autoimmune diseases, cardiovascular diseases, infections, or viral diseases, comprising combining one or more salts of guanidine derivatives corresponding to the formula



wherein

X represents $-CH_2-NH-NH-$ or $-CH=N-NH-$,

R represents a linear or branched C_1-C_{30} alkyl, C_3-C_{20} cycloalkyl, or tricyclodecyl residue, which can be substituted by one or more hydroxyl groups, C_1-C_4 alkoxy groups, C_1-C_4 alkyl groups and/or one or more halogen atoms or one or more amino groups, and

Z represents O-CO-Y, $O-S(O)_2-Y$, or O-P(O)(OH)-Y, wherein Y represents a linear or branched C_1-C_{12} alkyl, C_3-C_8 cycloalkyl, benzyl, furyl or pyridyl residue, which can be substituted by one or more hydroxyl groups, carboxylic acid groups, C_1-C_4 alkoxy groups, C_1-C_4 alkyl groups and/or one or more halogen atoms or one or more amino groups, ~~processing a salt according to Claim 2~~ with ~~common~~ a pharmaceutically acceptable additives and/or excipients to produce an administrable form.

16. (Currently Amended) Method according to Claim 15, comprising: ~~wherein the salt is processed to an administrable form by~~ providing approximately equimolar amounts of the corresponding base and acid, and combining the base and acid with the pharmaceutically acceptable ~~processing with common~~ additives and/or excipients.

17. (Cancelled)

18. (Currently Amended) Method for the treatment of tumor diseases, autoimmune diseases, cardiovascular diseases, infections, or viral diseases comprising administering to a patient a pharmaceutically effective amount of the pharmaceutical preparation of claim 1 ~~salt of Claim 2~~.